Wet AMD and DME Drug Development 2022

The second edition of the industry-led Wet AMD and DME Drug Development Summit arrives in Boston to give you comprehensive insight into the current and emerging angiogenesis- inflammatory-directed and anti-fibrotic drug development programs for these three ophthalmic conditions – neovascular age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and diabetic macular edema (DME).

Join this dedicated industry forum to network online and learn from senior leaders of discovery, translational sciences, and clinical development from the likes of Roche, Genentech, Novartis, Apellis, Outlook Therapeutics and more, to address the specific challenges for the biopharmaceutical and biotechnology in its efforts to bring long-lasting treatments which reduce clinical burden and can be commercialized to become the new standard-of-care in this vast ophthalmology indication.

Navigate across 3 jam-packed days including two interactive workshops exploring the optimization of administration techniques and viral and non-viral vectors to deliver safe and durable anti-angiogenic therapies to the eye and developing preclinical and translational models to predict human disease and efficacy of a drug.

Earlybird and group booking discounts available, visit the website for more information.